Lilly adds another sales channel for obesity drug Zepbound
Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.
Newsletters and Deep Dive digital magazine
Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.
Healthcare marketers looking for a fresh way to engage audiences across a wide range of demographics have turned to what may seem like an unusual source – sports.
Private equity group Blackstone is reported to be thinking of pulling out of a consortium to buy ophthalmology specialist Bausch + Lomb.
A non-invasive device that could help millions of women in the US with a condition known as pelvic organ prolapse (POP) has launched in the US.
Launching a product is always an intense, pivotal moment, but in a fast moving era of scientific advances and regulatory change, it has become an even more critical enterprise.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks